← All trials
NCT03715322
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2018
- Primary completion
- Apr 30, 2020
- Completion date
- Jun 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 350
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou Medical UniversityLead sponsor
- Guangzhou Medical UniversityOverall official - principal investigator
- Guangzhou Medical UniversityStudy chair
- Guangzhou Medical UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.